Stephen Willey Analyst Performance

Managing Director at Stifel Nicolaus

Stephen Willey is a stock analyst at Stifel Nicolaus focused in the medical sector, covering 26 publicly traded companies. Over the past year, Stephen Willey has issued 23 stock ratings, including buy and hold recommendations. While full access to Stephen Willey's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Stephen Willey's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 55 Last 10 Years
Buy Recommendations: 74.51% 38 Buy Ratings
Companies Covered: 26 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	74.5%	38 ratings
Hold	25.5%	13 ratings
Sell	0.0%	0 ratings

Out of 51 total stock ratings issued by Stephen Willey at Stifel Nicolaus, the majority (74.5%) have been Buy recommendations, followed by 25.5% Hold.

Best & Worst Calls

Best Call
000.0%
MLNT
Oct 2014
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
INO
Apr 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	92.3% of companies on NASDAQ	24 companies
NYSE	7.7% of companies on NYSE	2 companies

Stephen Willey, an analyst at Stifel Nicolaus, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 25 companies	96.2%
	Miscellaneous 1 company	3.8%

Stephen Willey of Stifel Nicolaus specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 13 companies	50.0%
PHARMACEUTICAL PREPARATIONS 7 companies	26.9%
MED - DRUGS 1 company	3.8%
MED PRODUCTS 1 company	3.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES 1 company	3.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	3.8%
BIOTECHNOLOGY 1 company	3.8%
Miscellaneous 1 company	3.8%

About Stephen Willey

Stephen Willey joined Stifel in 2010 with the acquisition of Thomas Weisel Partners LLC. Stephen is a Managing Director in the Healthcare sector, covering Biotechnology. Before joining Thomas Weisel Partners, Steven worked in research as a Research Scientist at ImClone Systems and as a Research Associate at Mount Sinai School of Medicine. Stephen received an undergraduate degree from University of New Hampshire, earned an MBA from New York University, and an M.S. from University of Rhode Island.

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
XFOR X4 Pharmaceuticals	8/29/2025	Lower Price Target	$4.12	$9.00	Buy
NKTX Nkarta	8/14/2025	Lower Price Target	$2.21	$12.00	Buy
INSM Insmed	8/14/2025	Boost Price Target	$125.13	$145.00	Buy
ABCL AbCellera Biologics	8/8/2025	Lower Price Target	$4.13	$7.00	Buy
EXEL Exelixis	7/29/2025	Boost Price Target	$44.39	$41.00	Hold
CELC Celcuity	7/1/2025	Initiated Coverage	$13.35	$30.00	Buy
CBIO Crescent Biopharma	6/25/2025	Initiated Coverage	$15.06	$28.00	Buy
INCY Incyte	6/16/2025	Upgrade	$67.75	$107.00	Buy
MGNX MacroGenics	5/14/2025	Lower Price Target	$1.53	$5.00	Hold
EXEL Exelixis	5/14/2025	Boost Price Target	$43.58	$38.00	Hold
BOLT Bolt Biotherapeutics	5/13/2025	Lower Price Target	$7.00	$20.00	Hold
NRIX Nurix Therapeutics	4/9/2025	Lower Price Target	$8.88	$35.00	Buy
NKTX Nkarta	3/27/2025	Lower Price Target	$1.37	$14.00	Buy
BOLT Bolt Biotherapeutics	3/25/2025	Lower Price Target	$8.75	$25.00	Hold
VOR Vor Biopharma	3/21/2025	Lower Price Target	$0.85	$5.00	Buy
ABCL AbCellera Biologics	2/28/2025	Lower Price Target	$2.93	$10.00	Buy
GERN Geron	2/27/2025	Lower Price Target	$1.62	$4.00	Buy
INSM Insmed	2/21/2025	Lower Price Target	$84.49	$96.00	Buy
EXEL Exelixis	2/12/2025	Boost Price Target	$35.11	$36.00	Hold
INSM Insmed	2/11/2025	Boost Price Target	$78.94	$97.00	Buy
INCY Incyte	2/10/2025	Boost Price Target	$68.30	$77.00	Hold
NRIX Nurix Therapeutics	1/29/2025	Boost Price Target	$19.56	$36.00	Buy
IGMS IGM Biosciences	1/10/2025	Downgrade	$6.20	$2.50	Hold

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.